InnoCare Pharma Ltd recently said that, driven by robust sales of its flagship anti-cancer drug and income from overseas licensing agreements, it expects to more than double its revenue in 2025 and achieve its first annual profit. This would mark the company's first full-year return to profitability since its founding.

The company forecast revenue of about 2.37 billion yuan ($330 million) for the year ended Dec 31, up around 134 percent from a year earlier, according to a preliminary earnings statement on Thursday. It expects net profit attributable to shareholders to be roughly 630 million yuan.

InnoCare, founded in 2015 and dual-listed in Shanghai and Hong Kong stock markets, said the turnaround was driven by rising sales of commercialized drugs and proceeds from global business development agreements.

Sales growth was led by orelabrutinib, the company's core product, as demand rose for its approved indications, including marginal zone lymphoma. Revenue was further boosted after the drug gained approval for first-line treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.

Another contributor was tafasitamab, which became China's first approved CD19 monoclonal antibody for relapsed or refractory diffuse large B-cell lymphoma, according to the company.

The company said 2025 marked solid progress in its so-called 2.0 strategy, with multiple regulatory and clinical milestones across its pipelines. Orelabrutinib was added to China's national drug reimbursement list for all four of its approved indications and was included as a category I recommendation in the 2025 CSCO lymphoma treatment guidelines. It was also approved in Singapore for relapsed or refractory marginal zone lymphoma.

InnoCare said its next-generation TRK inhibitor zurletrectinib won approval in China for patients with NTRK gene fusion-positive solid tumors, while its BCL-2 inhibitor mesutoclax advanced in late-stage clinical trials and received breakthrough therapy designation, the first granted to a BCL-2 inhibitor in China.

In addition, InnoCare received upfront and near-term payments in 2025 from licensing deals with Prolium Bioscience and Zenas BioPharma, including a $100 million upfront payment linked to the out-licensing of orelabrutinib and two preclinical assets.

Separately, the company reported progress across its TYK2 inhibitor program on Monday, including late-stage trials for atopic dermatitis and psoriasis, and said its antibody-drug conjugate platform reached a milestone with its first candidate entering clinical development.